Skip to main content

Table 1 Comparison of the numerical background of D2T RA cases by treatment types. Subgroups are compared using one-way analysis of variance (ANOVA) for numerical variables and chi-squared test for categorical variables

From: Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry

  TNFi (N = 71) IL-6Ri (N = 79) CTLA4-Ig (N = 58) JAKi (N = 145) p
Mean SE Median Mean SE Median Mean SE Median Mean SE Median
Numerical variables
Age 63.5 1.8 67 68.6 1.2 70 64.6 1.6 67.5 60.5 1.1 63 < 0.01*
Duration (months) 163.3 13.3 155 169.8 14.0 136 182.9 16.8 143 164.3 9.6 123 0.76
CDAI 27.4 1.5 26.2 28.9 1.6 26.2 26.7 1.4 24.8 26.2 1.0 25 0.5
HAQ-DI 1.6 0.1 1.5 1.6 0.1 1.6 1.6 0.1 1.6 1.4 0.1 1.4 0.19
DAS28-CRP 4.9 0.1 5.0 5.0 0.1 4.7 4.6 0.1 4.5 4.5 0.1 4.6 0.05
DAS28-ESR 5.7 0.1 5.8 5.9 0.1 5.8 5.3 0.2 5.2 5.2 0.1 5.4 < 0.01*
GC dose (mg/day)a 1.2 0.3 0 1.3 0.3 0 1.5 0.3 0 1.1 0.2 0 0.75
MTX dose (mg/week) 5.5 0.7 6 4.9 0.6 0 6.0 0.9 5 7.1 0.5 8 0.04
Creatinine (mg/dL) 0.9 0.1 0.68 0.9 0.1 0.76 0.7 0.0 0.64 0.7 0.0 0.65 0.03*
Categorical variables N % N % N % N % p
Gender Male 9 12.7 12 15.2 7 12.1 24 16.6 0.81
Female 62 87.3 67 84.8 51 87.9 121 83.4
ACPA Negative 10 14.1 17 21.5 9 15.5 34 23.4 0.36
Positive 57 80.3 57 72.2 49 84.5 111 76.6
Disease activity LDA 1 1.4 4 5.1 0 0.0 10 6.9 0.53
MDA 26 36.6 27 34.2 21 36.2 49 33.8
HDA 44 62.0 48 60.8 37 63.8 85 58.6
Use of MTX 38 53.5 39 49.4 31 53.4 92 63.4 0.18
Use of GC 19 26.8 16 20.3 19 32.8 29 20.0 0.20
Chronic lung disease 25 35.2 32 40.5 20 34.5 41 28.3 0.31
Chronic heart disease 2 2.8 12 15.2 2 3.4 2 0.7 < 0.01
Osteoporosis with fracture 3 4.2 3 1.3 3 5.2 1 0.7 0.98
Past use of b/tsDMARD TL 20 28.2 1 1.3 45 77.6 43 29.7 N.A
TA 14 19.7 53 67.1 0 0.0 22 15.2
TJ 4 5.6 7 8.9 7 12.1 17 11.7
LA 6 8.5 0 0.0 0 0.0 5 3.4
LJ 2 2.8 0 0.0 0 0.0 0 0.0
AJ 0 0.0 1 1.3 0 0.0 0 0.0
TLA 20 28.2 0 0.0 0 0.0 24 16.6
TAJ 0 0.0 12 15.2 0 0.0 4 2.8
TLJ 1 1.4 2 2.5 6 10.3 11 7.6
TLAJ 4 5.6 3 3.8 0 0.0 19 13.1
vD2T RA 25 35.2 17 21.5 6 10.3 58 40.0 < 0.01*
  1. D2T RA difficult-to-treat rheumatoid arthritis, b/tsDMARD targeted synthetic disease-modifying anti-rheumatic drugs, TNFi tumour necrosis factor inhibitor, IL-6R, interleukin-6 receptor inhibitor, CTLA4-Ig cytotoxic T-lymphocyte–associated antigen-4 immunoglobulin, JAKi Janus kinase inhibitor, CDAI Clinical Disease Activity Index, HAQ-DI Health Assessment Questionnaire Disability Index, DAS disease activity score, CRP C-reactive protein, ESR erythrocyte sedimentation rate, MTX methotrexate, GC glucocorticoid, NA not applicable
  2. *p < 0.05
  3. a Prednisolone equivalent dose